Kane Biotech Inc. (CVE:KNE – Get Free Report) shares fell 13.3% during mid-day trading on Friday . The company traded as low as C$0.06 and last traded at C$0.07. 537,300 shares were traded during trading, an increase of 855% from the average session volume of 56,261 shares. The stock had previously closed at C$0.08.
Kane Biotech Trading Down 13.3%
The stock has a fifty day moving average of C$0.09 and a 200-day moving average of C$0.10. The company has a debt-to-equity ratio of -331.42, a quick ratio of 0.39 and a current ratio of 0.80. The company has a market cap of C$9.36 million, a PE ratio of 1.63 and a beta of 0.52.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
See Also
- Five stocks we like better than Kane Biotech
- Buy P&G Now, Before It Sets A New All-Time High
- Walmart Stock Alert: Big Price Move Expected Soon
- 3 Warren Buffett Stocks to Buy Now
- An Acquisition Just Made Dick’s the Most Exciting Stock in Retail
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
